Abstract
Ischemic stroke is one of the leading causes of mortality and permanent disability in developed countries. Stroke induces massive glutamate release, which in turn causes N-Methyl-D-aspartate (NMDA) receptor over-excitation and thus, calcium overload in neurons leading to cell death via apoptotic cascades. The kynurenine pathway is a complex enzymatic cascade of tryptophan catabolism, generating various neuroactive metabolites. One metabolite, kynurenic acid (KYNA), is a potent endogenous NMDA glutamate receptor antagonist, making it a possible therapeutic tool to decrease excitotoxicity and neuroinflammation. Recently, clinical investigations have shown that during the acute phase of ischemic stroke, kynurenine pathway is activated and peripheral levels of metabolites correlated with worse outcome. In this review, we set out to summarize the current literature on the connection of the kynurenine pathway and ischemic stroke and set a course for future investigations and potential drug development.
Keywords: Kynurenine, stroke, ischemia, immunomodulation, kynurenine analogue, excitotoxicity.
Current Medicinal Chemistry
Title:Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects
Volume: 25 Issue: 42
Author(s): Péter Hertelendy, József Toldi, Ferenc Fülöp and László Vécsei*
Affiliation:
- Department of Neurology, University of Szeged, Semmelweis u. 6, H-6725 Szeged,Hungary
Keywords: Kynurenine, stroke, ischemia, immunomodulation, kynurenine analogue, excitotoxicity.
Abstract: Ischemic stroke is one of the leading causes of mortality and permanent disability in developed countries. Stroke induces massive glutamate release, which in turn causes N-Methyl-D-aspartate (NMDA) receptor over-excitation and thus, calcium overload in neurons leading to cell death via apoptotic cascades. The kynurenine pathway is a complex enzymatic cascade of tryptophan catabolism, generating various neuroactive metabolites. One metabolite, kynurenic acid (KYNA), is a potent endogenous NMDA glutamate receptor antagonist, making it a possible therapeutic tool to decrease excitotoxicity and neuroinflammation. Recently, clinical investigations have shown that during the acute phase of ischemic stroke, kynurenine pathway is activated and peripheral levels of metabolites correlated with worse outcome. In this review, we set out to summarize the current literature on the connection of the kynurenine pathway and ischemic stroke and set a course for future investigations and potential drug development.
Export Options
About this article
Cite this article as:
Hertelendy Péter, Toldi József, Fülöp Ferenc and Vécsei László *, Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects, Current Medicinal Chemistry 2018; 25 (42) . https://dx.doi.org/10.2174/0929867325666180313113411
DOI https://dx.doi.org/10.2174/0929867325666180313113411 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Heart Failure with Preserved Ejection Fraction Management -
The Role of Sacubitril-Valsartan, Pirfenidone, Spironolactone and Empagliflozin:
Is Success a Series of Small Victories?
Current Pharmaceutical Design Graphical Abstracts:
Current Medical Imaging Berberine Encapsulated PLGA-PEG Nanoparticles Modulate PCSK-9 in HepG2 Cells
Cardiovascular & Hematological Disorders-Drug Targets Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1?
Current Neuropharmacology Mechanosensitive Channels: Therapeutic Targets in the Myocardium?
Current Pharmaceutical Design Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Risk Factors for Development of Heart Failure
Current Cardiology Reviews COVID-19 in G6PD-deficient Patients, Oxidative Stress, and Neuropathology
Current Topics in Medicinal Chemistry Conference Report (The XVth International Symposium of Brain Edema and Cellular Injury)
CNS & Neurological Disorders - Drug Targets Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Obesity: An Emerging Importance of Progenitors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Peptides as Therapeutic Agents or Drug Leads for Autoimmune, Hormone Dependent and Cardiovascular Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Titin and Troponin: Central Players in the Frank-Starling Mechanism of the Heart
Current Cardiology Reviews Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Poly (Adenosine Diphosphate Ribose) Polymerase-1 Single Nucleotide Polymorphism in the 3'-Untranslated Region for Ischemic Stroke Risk Reduction
Current Neurovascular Research Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Current Alzheimer Research Antioxidative Actions of Carvedilol in the Treatment of Hypertension
Current Cardiology Reviews TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Role of Magnetic Resonance Imaging in Myocardial Iron Assessment
Current Cardiology Reviews From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry